Search by Drug Name or NDC

    NDC 00310-4535-30 IMJUDO 300 mg/15mL Details

    IMJUDO 300 mg/15mL

    IMJUDO is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by AstraZeneca Pharmaceuticals LP. The primary component is TREMELIMUMAB.

    Product Information

    NDC 00310-4535
    Product ID 0310-4535_4c293d27-b307-4b99-8ab0-904cf3d0353b
    Associated GPIs
    GCN Sequence Number 083971
    GCN Sequence Number Description tremelimumab-actl VIAL 300MG/15ML INTRAVEN
    HIC3 V3J
    HIC3 Description CYTOTOXIC T-LYMPHOCYTE ANTIGEN(CTLA-4)RMC ANTIBODY
    GCN 53048
    HICL Sequence Number 048415
    HICL Sequence Number Description TREMELIMUMAB-ACTL
    Brand/Generic Brand
    Proprietary Name IMJUDO
    Proprietary Name Suffix n/a
    Non-Proprietary Name tremelimumab
    Product Type HUMAN PRESCRIPTION DRUG
    Dosage Form INJECTION, SOLUTION
    Route INTRAVENOUS
    Active Ingredient Strength 300
    Active Ingredient Units mg/15mL
    Substance Name TREMELIMUMAB
    Labeler Name AstraZeneca Pharmaceuticals LP
    Pharmaceutical Class n/a
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA761289
    Listing Certified Through 2024-12-31

    Package

    NDC 00310-4535-30 (00310453530)

    NDC Package Code 0310-4535-30
    Billing NDC 00310453530
    Package 1 VIAL in 1 CARTON (0310-4535-30) / 15 mL in 1 VIAL
    Marketing Start Date 2022-10-21
    NDC Exclude Flag N
    Pricing Information N/A